Skip to main content

Alzheimer's Disease

Scientists uncover 'root cause' of Alzheimer's disease in breakthrough study


Using a new animal model of Alzheimer’s disease, the study highlights a potential breakthrough in treatment strategies. Unlike current therapies that primarily target a single toxic protein linked to the disease, this research explores a more comprehensive approach.

A research team from the Institut de Neurociències at the Universitat Autònoma de Barcelona (INc-UAB) has identified how the two primary hallmarks of Alzheimer’s disease—tau protein and beta-amyloid—affect brain circuits in distinct yet complementary ways, particularly those involved in memory and emotions. The study, conducted in collaboration with the Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED) and the Universidad Pablo de Olavide (UPO), provides new insights into the mechanisms underlying the disease.

Published in Molecular Psychiatry, the research shows that tau accumulation in the hippocampus primarily contributes to memory deficits, while beta-amyloid buildup in the amygdala leads to emotional disturbances such as anxiety and fear—both of which are early symptoms of Alzheimer’s. Furthermore, the presence of both pathologies together exacerbates brain inflammation and dysfunction, amplifying their overall impact on cognitive and emotional health.

For decades, research into Alzheimer’s disease has been shaped by two theories: one suggesting that the disease originates from tau buildup inside neurons, and another pointing to beta-amyloid accumulation as the primary trigger. These perspectives have largely dictated current therapeutic approaches, with treatments aiming to prevent the buildup of either tau or beta-amyloid in hopes of slowing disease progression.

However, the research team led by researchers Carles Saura and Arnaldo Parra-Damas, from the UAB Department of Biochemistry and Molecular Biology and the INc-UAB, argues that a dual-targeted therapeutic strategy may be necessary to effectively combat this disease.
A New Transgenic Mouse Model

This breakthrough was made possible by the development of a novel transgenic mouse model that replicates both tau and beta-amyloid pathologies. “Although both proteins accumulate in the brains of Alzheimer’s patients, most animal models used for studying the disease typically focus on only one of these factors,” explains researcher Maria Dolores Capilla, lead author of the study.

“In our research, we generated a transgenic mouse model exhibiting both tau and beta-amyloid accumulation, allowing us to analyze their individual and combined effects,” adds the INc-UAB researcher.

These findings could reshape current treatment strategies, which often target only one of these toxic proteins.

“Existing therapies have not achieved clear clinical benefits. Our study suggests that a therapeutic approach addressing multiple disease mechanisms—such as phosphorylated tau and beta-amyloid—could be more effective,” concludes Carles Saura.

While further research is needed to confirm its applicability to humans, this study represents a significant step toward new investigative pathways for Alzheimer’s treatment, the research team concludes.

Reference: “Synaptic vulnerability to amyloid-β and tau pathologies differentially disrupts emotional and memory neural circuits” by Maria Dolores Capilla-López, Angel Deprada, Yuniesky Andrade-Talavera, Irene Martínez-Gallego, Heriberto Coatl-Cuaya, Paula Sotillo, José Rodríguez-Alvarez, Antonio Rodríguez-Moreno, Arnaldo Parra-Damas and Carlos A. Saura, 30 January 2025, Molecular Psychiatry.

Alzheimer's disease, dementia, neurodegeneration, memory loss, cognitive decline, brain health, amyloid plaques, tau tangles, neurological disorder, mild cognitive impairment, aging brain, neuroinflammation, early diagnosis, risk factors, genetic predisposition, caregiving, behavioral changes, mental decline, treatment research, Alzheimer's prevention,

#AlzheimersDisease #DementiaAwareness #Neurodegeneration #MemoryLoss #CognitiveDecline #BrainHealth #AmyloidPlaques #TauTangles #NeurologicalDisorder #MildCognitiveImpairment #AgingBrain #Neuroinflammation #EarlyDiagnosis #RiskFactors #GeneticPredisposition #AlzheimersCare #BehavioralChanges #MentalDecline #TreatmentResearch #AlzheimersPrevention

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more